Surrozen Q2 FY26 net income rises to $50.18 million; revenue climbs to $5 million - SRZN News | RalliesSurrozen Q2 FY26 net income rises to $50.18 million; revenue climbs to $5 million
S
SRZN• Pipeline updates
- Surrozen targets an SZN-8141 IND filing by end-Q3 2026.
- The company plans to start the DUET Phase 1b/2a DME trial by year-end.
Q2 financial results
- Surrozen posted Q2 net income of $50.2 million, up from $39.7 million a year earlier.
- Revenue rose to $5 million from $983,000, driven by a Boehringer Ingelheim milestone.
- Operating loss widened to $10.37 million from $9.02 million as R&D spending climbed to $8.5 million from $6 million.
- Cash and cash equivalents slipped to $102 million at June 30 from $106.9 million at March 31.
•
